0001104659-14-026043.txt : 20140507 0001104659-14-026043.hdr.sgml : 20140507 20140407061026 ACCESSION NUMBER: 0001104659-14-026043 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20140407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc CENTRAL INDEX KEY: 0001328143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 421560076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2200 POWELL ST SUITE 220 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-903-3402 MAIL ADDRESS: STREET 1: 2200 POWELL ST SUITE 220 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc DATE OF NAME CHANGE: 20050524 CORRESP 1 filename1.htm

 

April 4, 2014

 

Credit Suisse Securities (USA) LLC

11 Madison Avenue

New York, New York 10010

 

Piper Jaffray & Co.

800 Nicollet Mall, Suite #800

Minneapolis, MN 55402

 

Mr. Jeffrey P. Riedler
Assistant Director

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549-3628

 

Re:

 

Request for Effectiveness for Registration Statement on Form S-1 of Adamas Pharmaceuticals, Inc. (File No. 333-194342)

 

Dear Mr. Riedler:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Adamas Pharmaceuticals, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern Time on April 8, 2014, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective.

 

Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s preliminary prospectus dated March 26, 2014:

 

(i)            Dates of distribution: March 26, 2014 through the date hereof

 

(ii)           Number of prospective underwriters to which the preliminary prospectus was furnished: 4

 

(iii)          Number of prospectuses furnished to investors: approximately 2,536

 

(iv)          Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants, and underwriters’ counsel: approximately 155

 

We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 


 

 

Very truly yours,

 

 

 

CREDIT SUISSE SECURITIES (USA) LLC

PIPER JAFFRAY & CO.

 

 

 

Acting severally on behalf of themselves and the

several underwriters

 

 

 

By:

CREDIT SUISSE SECURITIES (USA) LLC

 

 

 

 

 

 

 

By:

/s/ Charles Newton

 

 

Name:

Charles Newton

 

 

Title:

Managing Director

 

 

 

 

 

 

 

By:

PIPER JAFFRAY & CO.

 

 

 

 

 

 

 

By:

/s/ Udit Patel

 

 

Name:

Udit Patel

 

 

Title:

Vice President

 

[Signature Page to Underwriters’ Acceleration Request]